By bioengineering recombinant cell‐penetrating SOCS1 and SOCS3, we introduced a new class of anti‐inflammatory intracellular protein therapy.21, 154, 155 Within minutes, CP‐SOCS3 replenished the intracellular stores of SOCS3 that would be consumed during acute liver inflammation (see Figure 3). The gene discussed is SOCS3; the disease is inflammation.